Mn Services Vermogensbeheer B.V. Acquires 8,500 Shares of Gilead Sciences, Inc. $GILD

Mn Services Vermogensbeheer B.V. grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 474,555 shares of the biopharmaceutical company’s stock after acquiring an additional 8,500 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in Gilead Sciences were worth $52,676,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Gilead Sciences by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock valued at $13,233,912,000 after purchasing an additional 1,893,401 shares during the period. Geode Capital Management LLC raised its holdings in Gilead Sciences by 2.6% during the 2nd quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock worth $3,231,548,000 after buying an additional 727,515 shares during the period. Norges Bank bought a new position in Gilead Sciences in the second quarter valued at approximately $2,150,268,000. Invesco Ltd. lifted its stake in Gilead Sciences by 33.5% in the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after buying an additional 3,394,330 shares in the last quarter. Finally, Amundi boosted its holdings in shares of Gilead Sciences by 18.2% in the second quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock valued at $1,167,221,000 after buying an additional 1,614,355 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction on Monday, December 29th. The shares were sold at an average price of $124.83, for a total transaction of $1,248,300.00. Following the sale, the chief executive officer directly owned 566,698 shares of the company’s stock, valued at approximately $70,740,911.34. This represents a 1.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Kelly A. Kramer sold 2,805 shares of the stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.10, for a total transaction of $356,515.50. Following the completion of the sale, the director owned 1,339 shares of the company’s stock, valued at approximately $170,186.90. This represents a 67.69% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 141,757 shares of company stock worth $17,569,112. Insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Rothschild & Co Redburn raised their price objective on shares of Gilead Sciences from $153.00 to $159.00 and gave the stock a “buy” rating in a report on Tuesday. Scotiabank began coverage on Gilead Sciences in a report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 target price for the company. BMO Capital Markets reissued an “outperform” rating on shares of Gilead Sciences in a research note on Tuesday, January 13th. TD Cowen boosted their price target on Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Finally, Citigroup increased their price objective on Gilead Sciences from $135.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average price target of $133.52.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $135.93 on Friday. The stock has a market capitalization of $168.65 billion, a price-to-earnings ratio of 21.07, a PEG ratio of 0.69 and a beta of 0.33. The business has a 50-day moving average of $123.98 and a 200-day moving average of $118.62. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. Gilead Sciences, Inc. has a fifty-two week low of $92.26 and a fifty-two week high of $136.30.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same quarter in the prior year, the company posted $2.02 earnings per share. Gilead Sciences’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were given a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.3%. Gilead Sciences’s payout ratio is 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.